ClinicalTrials.gg
RecruitingNCT07303582ICEUpdated Nov 5, 2026

Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities

A Phase 4 interventional study of Cryoneurolysis and Botulinum toxin in Centreal Neurological Condition, Acquired Brain Injury (Including Stroke) and Multiple Sclerosis, sponsored by Oxford University Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Oxford University Hospitals NHS Trust · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Brain Injuries with a site in United Kingdom — 5 open to participants now, 5 under way, none of them phase 3. Brain Injuries · United Kingdom.

Planned enrollment
9th of 30
50 · median 28
Started
2025
with 1 other
Phase 4
2 of 40
1 open now
Registered
38th of 40
by date
Lead sponsor
2 of 40
Oxford University Hospitals NHS Trust

Among the 40 studies in Brain Injuries with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 38th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

5 of the 40 studies in Brain Injuries with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Brain Injuries with a site in United Kingdom, or all of them as a file.
02

Study summary

Spasticity is an umbrella term for impairments of muscle tone and control in people with damage to the brain and spinal cord. It is highly prevalent and results in pain, stiffness, and contribute to difficulties in activities of daily living. Current treatment options are limited, and many people experience only partial reduction in spasticity and frequent repeated treatments are needed.

Cryoneurolysis is a medical technique which involves the controlled freezing of the nerves. It has been approved in the UK for the treatment of pain in the context of spasticity through the targeting of nerves which control problematic muscles. Oxford University Hospitals NHS Foundation Trust has been offering this treatment routinely since January 2024. This pilot study aims to improve the understanding of the potential effectiveness of this treatment and its potential side effects when compared with a more commonly used treatment (Botulinum Toxin).

Participants will be randomly allocated to receive usual care with Botulinum Toxin (control group) or usual care with Cryoneurolysis (intervention group). The investigators will assess pain, goal attainment, side effects, spasticity, disability and independence in daily activities, and movement of the arm and leg. Assessments will be at baseline and then 6-, 12-, 18-, and 24-weeks following treatment. Participants who are randomised to the control group will have the opportunity to receive cryoneurolysis treatment after the 12 week follow up assessment.

The results of this study will help to guide future studies to examine the effectiveness of this treatment.

Read the detailed description

Spasticity is an umbrella term for impairments of muscle activity and control in the context of damage or dysfunction in the central nervous system, occurring in up to 87% of spinal cord injury patients, 42% of stroke patients, and 80% of patients with multiple sclerosis. Spasticity results in pain, stiffness, and restrictions to activity including difficulties in personal care and mobility and a significant impact on quality of life.

Treatments including oral medications, botulinum toxin injections, and physical therapies can provide some degree of relief, but effectiveness varies widely. Many patients experience only partial reduction in spasticity, contributing to ongoing functional limitations. Botulinum toxin injections provide temporary relief necessitating frequent treatments (every 3-4 months). This is burdensome for patients and healthcare providers, with associated time and treatment costs. Pharmacological treatments can lead to systemic side effects including drowsiness, dizziness, and cognitive impairments. Surgical interventions are resource-intensive and require specialised medical facilities. Their associated costs, in terms of financial resources and healthcare infrastructure, significantly limit access for certain patients.

Cryoneurolysis, a novel medical technique, involves the controlled freezing of nerve tissue to temporarily disrupt its function. While primarily used for pain, there is a growing interest in its application for managing spasticity and it is currently approved for the treatment of pain in the context of spasticity at Oxford University Hospitals NHS Trust. Observational studies suggest immediate relaxation of the affected muscles, resulting in improved joint range of motion, enhanced functional mobility, and reduced pain. The investigators' own open-label proof-of-principle clinical data suggest the potential for substantial improvements in the impact of spasticity on quality of life.

This pilot randomised controlled study aims to improve the understanding of the potential clinical effectiveness and side effect profile of cryoneurolysis as a treatment for pain in the context of spasticity in people with a range of neurological conditions (e.g. acquired brain injury (ABI), spinal cord injury, stroke, multiple sclerosis).

03

Conditions studied

  • Centreal Neurological Condition
  • Acquired Brain Injury (Including Stroke)
  • Multiple Sclerosis
  • Spinal Cord Injury

Keywords

  • Cryoneurolysis
  • Spasticity
  • Pain
  • Acquired Brain Injury
  • Stroke
  • Multiple Sclerosis
  • Spinal Cord Injury
  • Central Neurological Condition
  • Botulinum Toxin (botox)
  • Iovera
  • Chemodenervation
  • BoNT-A
  • Cryoneurotomy
  • Cryoneurectomy
  • Cryoanalgesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the trial OR a positive opinion from a consultee is provided by a family member or carer (relative or friend) willing to provide personal consultee (PC) advice.
  • Male or Female, aged 18 years or above.
  • Diagnosed with a central neurological condition, including acquired brain injury (e.g. from ischaemic stroke, trauma, or haemorrhage), multiple sclerosis, and spinal cord injury.
  • Clinical indication for Botulinum Toxin and Cryoneurolysis treatment, including pain associated with spasticity and with a response to diagnostic nerve block to specific nerves or nerve branches that can be treated with cryoneurolysis.
  • At least one rehabilitation goal related to management of pain resulting from spasticity.

Exclusion criteria

Exclusion Criteria:

  • Participant has received Botulinum toxin or cryoneurolysis within the last 90 days.
  • Raynaud's syndrome.
  • Cryoglobulinaemia.
  • Cold urticaria.
  • Bleeding disorders.
  • Localised infection at intended treatment site.
  • Planned oral antispasmodic medication dose changes.
  • Pregnancy, breastfeeding, or planning pregnancy in the trial period.
  • Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
  • Participants who are currently enrolled in another trial may be excluded if it is deemed (in the investigator's opinion) that participation could influence the results for either study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cryoneurolysis (+ usual care)

    Procedure: Cryoneurolysis

  • Active comparator
    Botulinum Toxin (+ usual care)

    Procedure: Botulinum toxin

Interventions

  • ProcedureCryoneurolysis

    Nerves that require treatment, and the number of treatments required for each nerve will be identified by routine clinical judgement. Nerve targets are identified using an ultrasound machine. The handheld Iovera cryoneurolysis device will be used for treatment. Participants will receive up to 4 treatments of cryoneurolysis for each nerve or nerve branch that requires treatment. It is anticipated that participants will have between 1 and 5 nerves or nerve branches per limb treated. Each Cryoneurolysis treatment takes 110 seconds. Total treatment time will be determined by number of nerves targeted and number of cryoneurolysis treatments per nerve. The shortest duration, with setup, is likely to be 60 minutes and the longest 120 minutes.

    Also known as: Iovera, Cryoneurotomy, Cryoneurectomy, Cryoanalgesia

  • ProcedureBotulinum toxin

    Muscles that require treatment with Botulinum Toxin will be identified by routine clinical assessment. Muscle targets will be identified using an ultrasound machine. It is anticipated that participants will have between 2 and 8 muscles identified for target. The participant will receive up to 200 units of Xeomin (Botulinum Toxin) per muscle that requires treatment. Treatment session of Botulinum Toxin will take 60 to 90 minutes.

    Also known as: Botox, Xeomin, Chemodenervation, BoNT-A

06

What researchers measure

Primary outcomes

  1. Goal Attainment Scale

    An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected).

    Time frame: 6-weeks post-treatment

Secondary outcomes

  1. Self-reported Pain

    Self-report, as measured by a numerical rating scale (range 0 - 10, higher scores indicating higher pain levels).

    Time frame: 6, 12, 18, and 24 weeks post-treatment

  2. Douleur Neuropathique en 4 (DN4)

    Questionnaire used to determine whether pain is neuropathic in origin (range 0 - 10; a score of 4 or more suggests the presence of neuropathic pain).

    Time frame: 6, 12, 18, and 24 weeks post-treatment

  3. Neuropathic Pain Symptom Inventory (NPSI)

    Questionnaire used to quantify neuropathic pain (range 0 - 100, higher scores reflect worse neuropathic pain).

    Time frame: 6, 12, 18, and 24 weeks post-treatment

  4. Side Effects

    As measured by self-report side effects questionnaire

    Time frame: 6, 12, 18, and 24 weeks post-treatment

  5. Goal Attainment Scale

    An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected).

    Time frame: 12-weeks post treatment

  6. Modified Ashworth Scale

    Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased in tone).

    Time frame: 6- and 12-weeks post treatment

  7. Modified Tardieu Scale

    Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased resistance).

    Time frame: 6- and 12-weeks post treatment

  8. Spasticity

    Directly assessed by measuring the muscle activity to a passive stretch

    Time frame: 6- and 12-weeks post treatment

  9. Range of Motion

    Assessed using a goniometer

    Time frame: 6- and 12-weeks post treatment

  10. Patient Reported Impact of Spasticity Measure (PRISM)

    Questionnaire assessing spasticity related quality of life (41 items that describe impacts of spasticity, each of which is rated on a scale of 0-4 from "never true for me" to "very often true for me").

    Time frame: 6- and 12-weeks post treatment

  11. EQ5D

    Questionnaire assessing quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels which are scored 1 - 5, with higher scores indicating worse outcome.

    Time frame: 6- and 12-weeks post treatment

  12. Spasticity Related Quality of Life instrument (SQoL-6D)

    Questionnaire assessing spasticity related quality of life (range 0 - 24, higher score indicating worse condition)

    Time frame: 6- and 12-weeks post treatment

  13. Barthel Index

    Scale measuring a person's ability to complete activities of daily living (range 0 - 100, higher scores indicating more independence)

    Time frame: 6- and 12-weeks post treatment

  14. Gait assessment - Walking Speed

    Kinematic assessment of lower extremity function, using EMG and motion capture cameras. Walking speed is measured in meters per second (m/s), with slower speed indicating worse outcome.

    Time frame: 6- and 12-weeks post treatment

  15. Gait assessment - Gait profile score

    Kinematic assessment of lower extremity function using EMG and motion capture cameras. The gait profile score is measured in degrees, with higher scores indicating more abnormality, and no maximum score.

    Time frame: 6- and 12-weeks post treatment

  16. Leg Activity Measure (LEG-A)

    Questionnaire assessing lower extremity function (3 sections: Section A range: 0-36; Section B range 0-60; Section C range 0 - 36. Higher score indicates more difficulty/severity.)

    Time frame: 6- and 12-weeks post treatment

  17. Shriners Hospital Upper Extremity Evaluation (SHUEE)

    Kinematic assessment of upper extremity function using motion capture cameras.

    Time frame: 6- and 12-weeks post treatment

  18. Arm Activity Measure (ARM-A)

    Questionnaire assessing upper extremity function (2 sections: Section A range: 0-32; Section B range 0-52. Higher score indicates more difficulty.)

    Time frame: 6- and 12-weeks post treatment

  19. Functional Assessment Test for Upper Limb (FAST-UL)

    Assessment of upper extremity function (selected movements assessed and scored between 0 - 3, with higher scores indicating ability to complete movement more fully).

    Time frame: 6- and 12-weeks post treatment

  20. Pressure Pain Thresholds (PPT)

    Sensory testing using a manual algometer to assess pain thresholds.

    Time frame: 6, 12, 18, and 24 weeks post-treatment

Other outcomes

  1. Feedback Questionnaire/Interview

    Qualitative feedback using either a semi-structured interview or a self-reported questionnaire (using the same questions as interview schedule), as per preference of participant, used to explore the satisfaction, experience, and anticipated barriers/facilitators to clinical implementation for the treatments.

    Time frame: 24 weeks post treatment

  2. Sleep Condition Indicator

    Questionnaire assessing self-reported insomnia symptoms (range 0-32, higher numbers indicate less symptoms of insomnia)

    Time frame: 6, 12, 18, and 24 weeks post-treatment

  3. Goal Attainment Scale

    An individualised outcome measure involving goal selection and goal scaling that is standardised in order to calculate the extent to which a patient's goals are met. GAS comprises of goals divided into a 5-point scale of level of expected outcome: from -2 (much less than expected) to +2 (much more than expected).

    Time frame: 18- and 24-weeks post-treatment

  4. Modified Ashworth Scale

    Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased in tone).

    Time frame: 18- and 24-weeks post-treatment

  5. Modified Tardieu Scale

    Assessment which requires the researcher to passively move the person's affected limb(s) and assess their resistance to movement (score range 0 - 4, higher score indicating increased resistance).

    Time frame: 18- and 24-weeks post-treatment

  6. Spasticity

    Directly assessed by measuring the muscle activity to a passive stretch

    Time frame: 18- and 24-weeks post-treatment

  7. Range of motion

    Assessed using a goniometer

    Time frame: 18- and 24-weeks post-treatment

  8. Patient Reported Impact of Spasticity Measure (PRISM)

    Questionnaire assessing spasticity related quality of life (41 items that describe impacts of spasticity, each of which is rated on a scale of 0-4 from "never true for me" to "very often true for me")

    Time frame: 18- and 24-weeks post-treatment

  9. EQ5D

    Questionnaire assessing quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels which are scored 1 - 5, with higher scores indicating worse outcome.

    Time frame: 18- and 24-weeks post-treatment

  10. Spasticity Related Quality of Life instrument (SQoL-6D)

    Questionnaire assessing spasticity related quality of life (range 0 - 24, higher score indicating worse condition)

    Time frame: 18- and 24-weeks post-treatment

  11. Barthel Index

    Scale measuring a person's ability to complete activities of daily living (range 0 - 100, higher scores indicating more independence)

    Time frame: 18- and 24-weeks post-treatment

  12. Leg Activity Measure (LEG-A)

    Questionnaire assessing lower extremity function (3 sections: Section A range: 0-36; Section B range 0-60; Section C range 0 - 36. Higher score indicates more difficulty/severity.)

    Time frame: 18- and 24-weeks post-treatment

  13. Arm Activity Measure (ARM-A)

    Questionnaire assessing upper extremity function (2 sections: Section A range: 0-32; Section B range 0-52. Higher score indicates more difficulty.)

    Time frame: 18- and 24-weeks post-treatment

07

Study locations

1 of 1 sites recruiting
  • Oxford Centre for Enablement (OUH NHS-FT)
    Oxford, OX3 7HE, United Kingdom
    Recruiting
    • Anton Pick, MBChB · Contactanton.pick@ouh.nhs.uk · +44 01865 737 306
    • Anton Pick, MBChB · Principal investigator
08

References and documents

Publications

  • Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013 Jan 15;80(3 Suppl 2):S13-9. doi: 10.1212/WNL.0b013e3182762448. PubMed 23319481 ↗
  • Winston P, Mills PB, Reebye R, Vincent D. Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use. Arch Rehabil Res Clin Transl. 2019 Oct 17;1(3-4):100030. doi: 10.1016/j.arrct.2019.100030. eCollection 2019 Dec. PubMed 33543059 ↗
  • Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19. PubMed 26092476 ↗
  • Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, Ashford S; Upper Limb International Spasticity (ULIS-III) study group. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med. 2021 Feb 24;53(2):jrm00157. doi: 10.2340/16501977-2801. PubMed 33616192 ↗
  • Skoog B, Jakobsson KE. Prevalence of Spasticity and Below-Level Neuropathic Pain Related to Spinal Cord Injury Level and Damage to the Lower Spinal Segments. J Rehabil Med Clin Commun. 2020 Mar 8;3:1000039. doi: 10.2340/20030711-1000039. eCollection 2020. PubMed 33884141 ↗
  • Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 Oct;10(5):589-95. doi: 10.1191/1352458504ms1085oa. PubMed 15471378 ↗
  • Kim PS, Ferrante FM. Cryoanalgesia: a novel treatment for hip adductor spasticity and obturator neuralgia. Anesthesiology. 1998 Aug;89(2):534-6. doi: 10.1097/00000542-199808000-00036. No abstract available. PubMed 9710418 ↗
  • Biel E, Aroke EN, Maye J, Zhang SJ. The applications of cryoneurolysis for acute and chronic pain management. Pain Pract. 2023 Feb;23(2):204-215. doi: 10.1111/papr.13182. Epub 2022 Dec 4. PubMed 36370129 ↗
  • Bhimani R, Anderson L. Clinical understanding of spasticity: implications for practice. Rehabil Res Pract. 2014;2014:279175. doi: 10.1155/2014/279175. Epub 2014 Sep 4. PubMed 25276432 ↗

Individual participant data

Plan to share: Yes — De-identified data are available upon reasonable request.

Supporting information: Study protocol

Time frame: Following publication of results

Access criteria: Available upon reasonable request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion May 2026 → Nov 2027 and completion Nov 2026 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Dec 26, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Nov 1, 2027was May 2026
CompletionEst.
Apr 1, 2028was Nov 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→Nov 1, 2027
Nov 5, 2026
Study completion
Nov 30, 2026→Apr 1, 2028
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion May 31, 2026→Nov 1, 2027
    Study completion Nov 30, 2026→Apr 1, 2028
    + 3 other changes: verification date, responsible party and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07303582
Lead sponsor
Oxford University Hospitals NHS Trust
Collaborators
University of Oxford, Bournemouth University
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Dec 2, 2025
Primary completion
Nov 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Anton Pick, MBChB
Contact
anton.pick@ouh.nhs.uk
(+44) 01865 737306
Barbara Robinson, MSc
Contact
barbara.robinson@ndcn.ox.ac.uk

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion